Age‐related increase in plasma p‐tau217 in amyloid‐beta–negative cognitively unimpaired individuals affects diagnostic interpretation

Source: PubMed Central Open Access, NCBI / U.S. National Library of Medicine

Abstract INTRODUCTION The extent to which non‐pathological aging influences plasma biomarkers remains unclear. Here, we investigate factors influencing plasma p‐tau217 levels in cognitively unimpaired (CU), amyloid‐beta–negative (Aβ‐) individuals. alz71532-sec-0010 METHODS Plasma p‐tau217 was measured in CU Aβ‐ positron emission tomography–negative (PET‐) participants using two immunoassays (ALZpath= 360 and LUMIPULSE G1200= 73). Associations between p‐tau217 and age groups (60–69, 70–79, and 80+ years), apolipoprotein E (genotype, and gender were evaluated. alz71532-sec-0020 RESULTS ALZpath plasma p‐tau217 showed a non‐pathological age‐related increase ( 0.05). Men had higher levels of p‐tau217 only with the ALZpath assay (= 0.02; Lumipulse:= 0.81). No significant associations were found between p‐tau217 andgenotype. alz71532-sec-0030 DISCUSSION Our results highlight the importance of incorporating age and sex into the interpretation of plasma p‐tau217 particularly in preclinical stages. alz71532-sec-0040 Highlights Plasma p‐tau217 increases with non‐pathological aging in cognitively unimpaired (CU) amyloid‐beta–negative (Aβ‐) individuals. ALZpath p‐tau217 intermediate‐zone rates increase with age. Lumipulse p‐tau217 shows age‐related positivity trends without significance. Sex differences observed with ALZpath p‐tau217; no apolipoprotein E (APOE) associations. bullet alz71532-list-0001 highlights